Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals Inc (NY: AMRX )

4.290 -0.060 (-1.38%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 295,580
Open 4.380
Bid (Size) 4.290 (5)
Ask (Size) 4.300 (15)
Prev. Close 4.350
Today's Range 4.170 - 4.380
52wk Range 1.240 - 4.730
Shares Outstanding 1,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amneal Reports Third Quarter 2023 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at Upcoming Investor Conferences
From Amneal Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+103.32%
+103.32%
1 Month
+10.57%
+10.57%
3 Month
+4.63%
+4.63%
6 Month
+83.33%
+83.33%
1 Year
+64.37%
+64.37%

More News

Read More
Why Asbury Automotive Group Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Analyst Ratings for Amneal Pharmaceuticals
Via Benzinga
General Electric, Verizon, Cleveland-Cliffs And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Amneal Reports Certain Preliminary Third Quarter 2023 Financial Results and Raises Full Year 2023 Financial Guidance
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Pharmaceuticals's Earnings: A Preview
Via Benzinga
Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio
From Amneal Pharmaceuticals, Inc.
Via Business Wire
NuScale Power, Stagwell And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Amneal to Report Third Quarter 2023 Results on November 7, 2023
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives First Product Approval in China
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Delegation from U.S. Department of Health and Human Services, U.S. Food and Drug Administration, and Local Government Officials Visit Amneal Manufacturing Site in India
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at the 2023 Wells Fargo Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why ResMed Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Amneal Pharmaceuticals Stock Gaines: It Raised FY23 Outlook On Prescription Trends, Pricing Levels Strength
Via Benzinga
Amneal Reports Second Quarter 2023 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For August 4, 2023
Via Benzinga
Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report Second Quarter 2023 Results on August 4, 2023
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.